- Samsung Biologics has launched an all-cash public tender offer to acquire PolyPeptide Group AG for CHF 44.31 per share, valuing the company at approximately CHF 1.46 billion.
- PolyPeptide also reported preliminary H1 2026 results, including 41.6% revenue growth to EUR 236.6 million, an EBITDA margin of 20.7%, and updated full-year guidance.
Samsung Biologics has announced an all-cash public tender offer to acquire all publicly held shares of PolyPeptide Group AG for CHF 44.31 per share, valuing the peptide-focused CDMO at approximately CHF 1.46 billion. The companies said they have entered into a transaction agreement, with the offer intended to provide PolyPeptide with additional resources, investment capacity, and a broader strategic platform. Samsung Biologics expects to publish its offer prospectus by August 31, 2026, with the transaction anticipated to close toward the end of 2026, subject to shareholder acceptance and regulatory approvals.
The offer price represents a 40% premium to PolyPeptide’s closing share price on April 10, 2026, before market rumors of a potential acquisition emerged, and an approximately 11.6% premium to the 60-day volume-weighted average share price. PolyPeptide’s Board of Directors, acting through its independent and non-conflicted members, unanimously recommends that shareholders accept the offer. The recommendation is supported by an independent fairness opinion from IFBC AG. Draupnir Holding B.V., which holds approximately 55.65% of the company’s shares, has committed to tender its entire stake. The transaction requires a minimum acceptance rate of 66⅔% on a fully diluted share basis, along with customary regulatory approvals.
Separately, PolyPeptide reported preliminary, unaudited financial results for the first half of 2026. Revenue increased 41.6% year over year to EUR 236.6 million, while the EBITDA margin improved to 20.7% from 2.7% in the prior-year period. The company reported an approximate profit of EUR 9 million for the period, compared with a loss of EUR 26.5 million in the first half of 2025. Growth was primarily driven by metabolic therapeutics, which accounted for approximately 68% of total revenue, while revenue from large pharmaceutical customers increased to around 72% of total revenue.
PolyPeptide also reported progress on its contract manufacturing capacity expansion, including its large-scale solid-phase peptide synthesis facility in Braine-l’Alleud, Belgium, which has operated at target utilization and higher yield since the beginning of the year. The company’s Phase III development pipeline expanded to 37 projects, and it updated its full-year 2026 guidance to 25–30% revenue growth at constant currency rates, a high-teens EBITDA margin, and capital expenditures of 15–20% of revenue.
“After a comprehensive review of strategic options, the Board is convinced that Samsung Biologics’ offer is compelling for our shareholders, delivering an attractive cash price and immediate, certain value today. At the same time, it represents a transformational opportunity to accelerate our strategic ambitions at a scale we could not reach alone – creating a stronger global partner for customers and a platform uniquely positioned to lead the next phase of growth in peptide-based therapeutics.”
Peter Wilden, Chairman of the Board of Directors of PolyPeptide
